Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1)

NCT01479868 is registered in ClinicalTrials.gov with Janssen R&D Ireland as lead sponsor.

NCT NCT01479868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01479868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1)
Lead sponsor
Janssen R&D Ireland
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2013
Enrollment
109 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus genotype-1